NB11 Stock Overview A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Vaxart Historical stock prices Current Share Price US$0.62 52 Week High US$1.33 52 Week Low US$0.44 Beta 0.62 1 Month Change 8.14% 3 Month Change -7.14% 1 Year Change 15.04% 3 Year Change -89.60% 5 Year Change 164.10% Change since IPO -10.43%
Recent News & Updates
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate Dec 03
Third quarter 2024 earnings released: US$0.062 loss per share (vs US$0.11 loss in 3Q 2023) Nov 16
Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate Oct 01
New major risk - Financial position Sep 11
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia Aug 28 See more updates
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate Dec 03
Third quarter 2024 earnings released: US$0.062 loss per share (vs US$0.11 loss in 3Q 2023) Nov 16
Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate Oct 01
New major risk - Financial position Sep 11
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia Aug 28
Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023) Aug 11
Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market Jul 06
Now 40% undervalued after recent price drop Jul 02
Now 21% undervalued after recent price drop Jun 19 Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023) May 15
Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024 May 09
Vaxart, Inc., Annual General Meeting, Jun 11, 2024 May 01
Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024 Mar 08 Vaxart, Inc. Announces Chief Executive Officer Changes
Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement Jan 20
New major risk - Share price stability Jan 17 Vaxart, Inc. Announces CEO Changes Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jan 16
Now 21% undervalued after recent price drop Jan 05
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers Dec 21
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers Nov 03
Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
New minor risk - Market cap size Oct 25
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate Sep 07
Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Jul 27
Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate Jul 12
Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index Jun 25
Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate Jun 07
First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022) May 07
Full year 2022 earnings released: US$0.84 loss per share (vs US$0.58 loss in FY 2021) Mar 17
Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate Feb 15
Vaxart, Inc. Names Phillip Lee as Chief Financial Officer Dec 20
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021) Nov 10
Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 21
Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate Sep 02
Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer Sep 01
Vaxart, Inc. Announces Board Changes Aug 26
Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors Aug 09
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.13 loss in 2Q 2021) Aug 09 Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022
Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive Jul 21
Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron Jun 05
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults Jun 03
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission May 20 Vaxart, Inc. Announces Management Changes
First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2021) May 11
No longer forecast to breakeven May 05
High number of new and inexperienced directors Apr 27
Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022 Apr 01
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel Feb 15
Forecast to breakeven in 2024 Jan 01
Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron Dec 17
Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc. Dec 02
No longer forecast to breakeven Nov 24
Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020) Nov 06
Forecast to breakeven in 2023 Sep 23
Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2020) Aug 08
Forecast to breakeven in 2023 Aug 08
Vaxart, Inc. Announces FDA Clearance IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate Aug 04
No longer forecast to breakeven Jul 27
No longer forecast to breakeven Jul 08
Vaxart, Inc. Announces First Subject Enrolled in Phase 1B Norovirus Dose-Ranging Trial in Elderly Adults May 08
Vaxart, Inc. Announces First Subject Enrolled in Phase 1B Norovirus Boosting Regimen Study May 05
First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.021 loss in 1Q 2020) May 04
Vaxart, Inc. Announces New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses May 04
New 90-day low: €4.74 Mar 06
Full year 2020 earnings released: US$0.36 loss per share (vs US$0.86 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Vaxart, Inc. Plans to Initiate the First Phase 2 Study of Its Oral Covid-19 Vaccine Candidate Feb 26
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral Covid-19 Tablet Vaccine Candidate Feb 04
Independent Director has left the company Feb 02
Independent Director has left the company Feb 02
Vaxart, Inc. Announces Board and Committee Resignations Jan 31
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication Jan 28
New 90-day high: €7.35 Jan 26
Widad and Rinani Dynamic Sdn. Bhd. Enters into Memorandum of Collaboration to the Distribution, Marketing and Sale of Oral Tablet Corona Virus Disease 2019 Developed by Vaxart, Inc Dec 16
Chairman recently sold €1.8m worth of stock Nov 26
Revenue misses expectations Nov 14
Third quarter 2020 earnings released: US$0.075 loss per share Nov 14
Vaxart, Inc. Announces Additional Data from Hamster Challenge Study of Its Oral COVID-19 Vaccine Nov 13
New 90-day low: €3.28 Nov 09
Vaxart, Inc. Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine Oct 15
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet Covid-19 Vaccine Oct 14 Shareholder Returns NB11 DE Biotechs DE Market 7D 15.4% -0.8% -1.6% 1Y 15.0% -13.0% 6.8%
See full shareholder returns
Return vs Market: NB11 exceeded the German Market which returned 6.8% over the past year.
Price Volatility Is NB11's price volatile compared to industry and market? NB11 volatility NB11 Average Weekly Movement 16.6% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: NB11's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NB11's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website n/a 109 Steven Lo vaxart.com
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Show more Vaxart, Inc. Fundamentals Summary How do Vaxart's earnings and revenue compare to its market cap? NB11 fundamental statistics Market cap €133.21m Earnings (TTM ) -€69.58m Revenue (TTM ) €16.12m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NB11 income statement (TTM ) Revenue US$16.76m Cost of Revenue US$66.26m Gross Profit -US$49.50m Other Expenses US$22.83m Earnings -US$72.34m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.32 Gross Margin -295.37% Net Profit Margin -431.61% Debt/Equity Ratio 7.1%
How did NB11 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 08:40 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Vaxart, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Charles Duncan Cantor Fitzgerald & Co. Vernon Bernardino H.C. Wainwright & Co.
Show 3 more analysts 
